ArticleScience signaling2013
Profiles of Basal and stimulated receptor signaling networks predict drug response in breast cancer lines.
Article in Science signaling, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 102 citations in OpenAlex.
- Copper-Iron Cell Death Axis: Mechanistic Crosstalk, Disease Implications and an Integrated Metallo-Redox-Metabolic Framework.International journal of biological sciences · 2026Review
- Systems Biology of the Cancer Cell.Annual review of biomedical engineering · 2025Review
- Large-scale information retrieval and correction of noisy pharmacogenomic datasets through residual thresholded deep matrix factorization.Briefings in bioinformatics · 2025Article
- Article
- A text-based computational framework for patient -specific modeling for classification of cancers.iScience · 2022Article
- RadSigBench: a framework for benchmarking functional genomics signatures of cancer cell radiosensitivity.Briefings in bioinformatics · 2022Article
- An overview of machine learning methods for monotherapy drug response prediction.Briefings in bioinformatics · 2022Article
- Can Systems Biology Advance Clinical Precision Oncology?Cancers · 2021Review
- Cell-to-cell and type-to-type heterogeneity of signaling networks: insights from the crowd.Molecular systems biology · 2021Article
- Data-Driven Computational Modeling Identifies Determinants of Glioblastoma Response to SHP2 Inhibition.Cancer research · 2021Article
- Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer.Cancer research · 2020Article
- Receptor-based mechanism of relative sensing and cell memory in mammalian signaling networks.eLife · 2020Article
- Robust latent-variable interpretation of in vivo regression models by nested resampling.Scientific reports · 2019Article
- Lower Tubulin Expression in Glioblastoma Stem Cells Attenuates Efficacy of Microtubule-Targeting Agents.ACS pharmacology & translational science · 2019Article
- Cheminformatics Tools for Analyzing and Designing Optimized Small-Molecule Collections and Libraries.Cell chemical biology · 2019Article
- Tensor clustering with algebraic constraints gives interpretable groups of crosstalk mechanisms in breast cancer.Journal of the Royal Society, Interface · 2019Article
- Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy.British journal of cancer · 2019Article
- Comprehensive anticancer drug response prediction based on a simple cell line-drug complex network model.BMC bioinformatics · 2019Article
- Carrier-Assisted Single-Tube Processing Approach for Targeted Proteomics Analysis of Low Numbers of Mammalian Cells.Analytical chemistry · 2019Article
- Dynamic Targeting in Cancer Treatment.Frontiers in physiology · 2019Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Identifying factors responsible for variation in drug response is essential for the effective use of targeted therapeutics. We profiled signaling pathway activity in a collection of breast cancer cell lines before and after stimulation with physiologically relevant ligands, which revealed the variability in network activity among cells of known genotype and molecular subtype. Despite the receptor-based classification of breast cancer subtypes, we found that the abundance and activity of signaling proteins in unstimulated cells (basal profile), as well as the activity of proteins in stimulated cells (signaling profile), varied within each subtype. Using a partial least-squares regression approach, we constructed models that significantly predicted sensitivity to 23 targeted therapeutics. For example, one model showed that the response to the growth factor receptor ligand heregulin effectively predicted the sensitivity of cells to drugs targeting the cell survival pathway mediated by PI3K (phosphoinositide 3-kinase) and Akt, whereas the abundance of Akt or the mutational status of the enzymes in the pathway did not. Thus, basal and signaling protein profiles may yield new biomarkers of drug sensitivity and enable the identification of appropriate therapies in cancers characterized by similar functional dysregulation of signaling networks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.